Cargando…
Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas
Bone and soft tissue sarcomas are a group of rare malignant tumours with major histological and anatomical varieties. In a metastatic setting, sarcomas have a poor prognosis due to limited response rates to chemotherapy. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may off...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161918/ https://www.ncbi.nlm.nih.gov/pubmed/36728839 http://dx.doi.org/10.1259/bjr.20220886 |
_version_ | 1785037595548319744 |
---|---|
author | Kleiburg, Fleur Heijmen, Linda Gelderblom, Hans Kielbasa, Szymon M Bovée, Judith VMG De Geus-Oei, Lioe-Fee |
author_facet | Kleiburg, Fleur Heijmen, Linda Gelderblom, Hans Kielbasa, Szymon M Bovée, Judith VMG De Geus-Oei, Lioe-Fee |
author_sort | Kleiburg, Fleur |
collection | PubMed |
description | Bone and soft tissue sarcomas are a group of rare malignant tumours with major histological and anatomical varieties. In a metastatic setting, sarcomas have a poor prognosis due to limited response rates to chemotherapy. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may offer a new perspective. PSMA is a type II transmembrane glycoprotein which is present in all prostatic tissue and overexpressed in prostate cancer. Despite the name, PSMA is not prostate-specific. PSMA expression is also found in a multitude of non-prostatic diseases including a subgroup of sarcomas, mostly in its neovascular endothelial cells. On PET/CT imaging, multiple sarcomas have also shown intense PSMA-tracer accumulation. PSMA expression and PSMA-tracer uptake seem to be highest in patients with aggressive and advanced sarcomas, who are also in highest need of new therapeutic options. Although these results provide a good rationale for the future use of PSMA-targeted radioligand therapy in a selection of sarcoma patients, more research is needed to gain insight into optimal patient selection methods, PSMA-targeting antibodies and tracers, administered doses of radioligand therapy, and their efficacy and tolerability. In this review, mRNA expression of the FOLH1 gene which encodes PSMA, PSMA immunohistochemistry, PSMA-targeted imaging and PSMA-targeted therapy in sarcomas will be discussed. |
format | Online Article Text |
id | pubmed-10161918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The British Institute of Radiology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101619182023-05-06 Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas Kleiburg, Fleur Heijmen, Linda Gelderblom, Hans Kielbasa, Szymon M Bovée, Judith VMG De Geus-Oei, Lioe-Fee Br J Radiol Review Article Bone and soft tissue sarcomas are a group of rare malignant tumours with major histological and anatomical varieties. In a metastatic setting, sarcomas have a poor prognosis due to limited response rates to chemotherapy. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may offer a new perspective. PSMA is a type II transmembrane glycoprotein which is present in all prostatic tissue and overexpressed in prostate cancer. Despite the name, PSMA is not prostate-specific. PSMA expression is also found in a multitude of non-prostatic diseases including a subgroup of sarcomas, mostly in its neovascular endothelial cells. On PET/CT imaging, multiple sarcomas have also shown intense PSMA-tracer accumulation. PSMA expression and PSMA-tracer uptake seem to be highest in patients with aggressive and advanced sarcomas, who are also in highest need of new therapeutic options. Although these results provide a good rationale for the future use of PSMA-targeted radioligand therapy in a selection of sarcoma patients, more research is needed to gain insight into optimal patient selection methods, PSMA-targeting antibodies and tracers, administered doses of radioligand therapy, and their efficacy and tolerability. In this review, mRNA expression of the FOLH1 gene which encodes PSMA, PSMA immunohistochemistry, PSMA-targeted imaging and PSMA-targeted therapy in sarcomas will be discussed. The British Institute of Radiology. 2023-05-01 2023-03-03 /pmc/articles/PMC10161918/ /pubmed/36728839 http://dx.doi.org/10.1259/bjr.20220886 Text en © 2023 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Article Kleiburg, Fleur Heijmen, Linda Gelderblom, Hans Kielbasa, Szymon M Bovée, Judith VMG De Geus-Oei, Lioe-Fee Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
title | Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
title_full | Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
title_fullStr | Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
title_full_unstemmed | Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
title_short | Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
title_sort | prostate-specific membrane antigen (psma) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161918/ https://www.ncbi.nlm.nih.gov/pubmed/36728839 http://dx.doi.org/10.1259/bjr.20220886 |
work_keys_str_mv | AT kleiburgfleur prostatespecificmembraneantigenpsmaasapotentialtargetformolecularimagingandtreatmentinboneandsofttissuesarcomas AT heijmenlinda prostatespecificmembraneantigenpsmaasapotentialtargetformolecularimagingandtreatmentinboneandsofttissuesarcomas AT gelderblomhans prostatespecificmembraneantigenpsmaasapotentialtargetformolecularimagingandtreatmentinboneandsofttissuesarcomas AT kielbasaszymonm prostatespecificmembraneantigenpsmaasapotentialtargetformolecularimagingandtreatmentinboneandsofttissuesarcomas AT boveejudithvmg prostatespecificmembraneantigenpsmaasapotentialtargetformolecularimagingandtreatmentinboneandsofttissuesarcomas AT degeusoeilioefee prostatespecificmembraneantigenpsmaasapotentialtargetformolecularimagingandtreatmentinboneandsofttissuesarcomas |